Joseph J Schildkraut1, John J Mooney. 1. Department of Psychiatry, Harvard Medical School at Massachusetts Mental Health Center, Chestnut Hill, MA 02467, USA. joseph_schildkraut@hms.harvard.edu
Abstract
OBJECTIVE: The authors considered the possible role of the extraneuronal monoamine transporter (uptake 2) in accounting for the delay in clinical action of norepinephrine reuptake inhibitor antidepressant drugs. METHOD: Literature searches were performed by means of the MEDLINE and Current Contents databases with search terms such as "extraneuronal uptake," "uptake 2," "extraneuronal monoamine transporter," and "organic cation transporter type-3." RESULTS: The findings in this literature indicate that inhibition of glial uptake 2 by normetanephrine or other inhibitors of uptake 2 would enhance the accumulation of norepinephrine in the synapse. CONCLUSIONS: The authors propose the hypothesis that drugs or other agents that increase levels of normetanephrine or otherwise inhibit the extraneuronal monoamine transporter, uptake 2, in the brain will speed up the clinical effects of norepinephrine reuptake inhibitor antidepressant drugs.
OBJECTIVE: The authors considered the possible role of the extraneuronal monoamine transporter (uptake 2) in accounting for the delay in clinical action of norepinephrine reuptake inhibitor antidepressant drugs. METHOD: Literature searches were performed by means of the MEDLINE and Current Contents databases with search terms such as "extraneuronal uptake," "uptake 2," "extraneuronal monoamine transporter," and "organic cation transporter type-3." RESULTS: The findings in this literature indicate that inhibition of glial uptake 2 by normetanephrine or other inhibitors of uptake 2 would enhance the accumulation of norepinephrine in the synapse. CONCLUSIONS: The authors propose the hypothesis that drugs or other agents that increase levels of normetanephrine or otherwise inhibit the extraneuronal monoamine transporter, uptake 2, in the brain will speed up the clinical effects of norepinephrine reuptake inhibitor antidepressant drugs.
Authors: Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws Journal: J Neurosci Date: 2013-06-19 Impact factor: 6.167
Authors: John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut Journal: J Psychiatr Res Date: 2007-08-28 Impact factor: 4.791
Authors: Nicole L Baganz; Rebecca E Horton; Alfredo S Calderon; W Anthony Owens; Jaclyn L Munn; Lora T Watts; Nina Koldzic-Zivanovic; Nathaniel A Jeske; Wouter Koek; Glenn M Toney; Lynette C Daws Journal: Proc Natl Acad Sci U S A Date: 2008-11-24 Impact factor: 11.205
Authors: Beverly H Brummett; Andrew D Krystal; Ilene C Siegler; Cynthia Kuhn; Richard S Surwit; Stephan Züchner; Allison Ashley-Koch; John C Barefoot; Redford B Williams Journal: Psychosom Med Date: 2007-06 Impact factor: 4.312